IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...

The hand sanitizer spray pen market is projected to grow at a CAGR of 11% over the forecast period, reaching a market value ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

Seven independent members of the company’s board resigned Tuesday, concluding that despite co-founder and CEO Anne Wojcicki’s ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

A group of lawmakers wants the U.S. Patent & Trademark Office and drug companies to change their approach toward handling ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...